

MINIREVIEW

Omega-3 Polyunsaturated Fatty Acids and Skeletal Health¹

BRUCE A. WATKINS,*†² YONG LI,* HUGH E. LIPPMAN,* AND MARK F. SEIFERT†

**Department of Food Science, Lipid Chemistry and Molecular Biology Laboratory, Purdue University, West Lafayette, Indiana 47907; †Department of Anatomy and Cell Biology, School of Medicine, Indiana University Purdue University Indianapolis, Indiana 46202*

This minireview on skeletal biology describes the actions of prostaglandins and cytokines involved in the local regulation of bone metabolism, it documents the role of lipids in bone biology, and it presents relationships between fatty acids and other factors that impact skeletal metabolism. The data presented herein show consistent and reproducible beneficial effects of omega-3 (n-3) fatty acids on bone metabolism and bone/joint diseases. Polyunsaturated fatty acids modulate eicosanoid biosynthesis in numerous tissues and cell types, alter signal transduction, and influence gene expression. These effects have not been explored in the skeletal system. Future research on n-3 fatty acids in bone biology should focus on the following two aspects. First, the further elucidation of how n-3 fatty acids alter biochemical and molecular processes involved in bone modeling and bone cell differentiation, and second, the evaluation of the potential pharmaceutical applications of these nutraceutical fatty acids in maintaining bone mineral status and controlling inflammatory bone/joint diseases.

[Exp Biol Med Vol. 226(6):485–497, 2001]

Key words: omega-3 fatty acids; bone; prostaglandins; osteoporosis; phytoestrogens

Dietary fat intake has remained a central focus of nutrition research in recent years and dietary guidelines for fat consumption continue to be updated in response to new information gained through epidemiological, clinical, and animal investigations (1). Links to cardiovascular disease (CVD), degenerative and inflammatory arthritis, cancer, and osteoporosis, and the recognition of fats and their derivatives as biological effectors of human pathologies serve to drive research on dietary lipids. The association of cholesterol and saturated fat with increased risk of CVD initially spurred dietary recommendations to reduce the intake of animal fat and to increase the intake of plant oils. The dramatic change in food formulations has led to a greater dietary intake of plant oils such as corn, safflower, and soybean oil, which are high in linoleic acid, and resulted in an elevated ratio of omega-6/omega-3 (n-6/n-3) fatty acids during the 20th century (2). Evidence suggests that the high intake of n-6 with an inadequate amount of n-3 fatty acids in the diet contributes to the development of certain cancers and some chronic diseases, including those of the skeletal system (bone/joint diseases).

Bone Modeling and Remodeling

Bone is a multifunctional organ that consists of a structural framework of mineralized matrix and contains heterogeneous populations of chondrocytes, osteoblasts, osteocytes, osteoclasts, endothelial cells, monocytes, macrophages, lymphocytes, and hemopoietic cells. This milieu of cells produces a variety of biological regulators that control local bone metabolism. Systemic calcitropic hormones (parathyroid hormones [PTH], estrogen, and 1,25-[OH]₂ vitamin D₃) and autocrine and paracrine factors, including prostaglandins, cytokines, and growth factors orchestrate the cellular activities of bone modeling to increase the length and diameter, and properly shape long bones in children. Bone grows in size and shape through the collective

Supported in part by the USDA National Research Initiative (grant no. 96-35200-313).

Approved as Journal Paper Number 16388 of the Purdue Agricultural Experiment Station.

To whom requests for reprints should be addressed at Department of Food Science, Lipid Chemistry and Molecular Biology Laboratory, Purdue University, West Lafayette, IN 47907. E-mail: watkins@foodsci.purdue.edu

0037-9727/01/2266-0485\$15.00

© 2001 by the Society for Experimental Biology and Medicine

activities of cells that produce, mineralize, and resorb bone matrix. Osteoblasts produce and mineralize bone matrix, while the specialized multinucleated cells called osteoclasts cause bone resorption (3). The combined and cooperative activities of osteoblasts and osteoclasts result in a bone architecture that provides mechanical support and protection for the body. In addition, bone serves as a vital reservoir of minerals, principally calcium and phosphorus, necessary for maintaining normal cellular, neurologic, and vascular activities of the body.

Long bone growth is regulated by complex interactions between an individual's genetic potential, environmental influences, and nutrition. Long bones of children increase in length and diameter by a process called modeling. Bone modeling represents an adaptive process of generalized and continuous growth and reshaping of bone governed by the activities of osteoblasts and osteoclasts until the adult bone structure is attained. This growth requires that bone cells function normally and that adequate nutrition is provided. Bone modeling is distinct from bone remodeling in that the latter describes the local, coupled process of bone resorption and formation that maintains skeletal mass and morphology in the adult. The numerous cell-derived growth regulatory factors present within skeletal tissues exert local controls on skeletal metabolism. The prostaglandins are major players in bone metabolism, as well as in bone/joint diseases. Many of the skeletal pathologies that afflict the adult, e.g., osteoporosis and rheumatoid arthritis, are the consequence of either abnormal bone remodeling and metabolism or an inflammatory process. Recent studies suggest that the onset and severity of some of these pathologies may be delayed and lessened if bone modeling is optimized early in life or if diets are supplemented with nutrients that reduce tissue concentrations of factors that undermine skeletal health.

Osteoblasts are mononucleated bone-forming cells that originate locally from mesenchymal stem cells. Osteoblasts are recruited to a site of bone formation where they actively synthesize and secrete an organic bone matrix called "osteoid," which is composed mainly of type I collagen and other noncollagenous proteins. Following its formation, osteoid normally undergoes rapid mineralization with hydroxyapatite. In addition to synthesizing bone matrix, osteoblasts maintain a high alkaline phosphatase activity and produce numerous regulatory factors, including prostaglandins, cytokines, and growth factors. These locally produced agents are reported to stimulate bone formation or bone resorption (4–7).

Osteoclasts are large multinucleated bone-resorbing cells. They are formed at skeletal sites from the fusion of mononuclear hemopoietic precursors that arrive via the vasculature. Active osteoclasts are in contact with mineralized surfaces and produce distinctive resorptive cavities called Howship's lacunae. During bone resorption, osteoclasts produce and release lysosomal enzymes, hydrogen protons, and free radicals into a confined space next to bone that dissolve the mineral and degrade bone matrix (8).

Regulation of Bone Metabolism

Bone formation and bone resorption are regulated by systemic hormones and local factors produced in bone (4–6, 9). Systemic hormones that sustain bone formation include insulin, growth hormone (10), and estrogen (11), while those that induce bone resorption include 1,25-(OH)₂ vitamin D₃ (12), PTH (13), thyroid hormone (14), and glucocorticoids (15, 16). In addition, calcitonin inhibits bone resorption (17). Even though several localized compounds act on bone cells, the prostaglandins (PG) seem to be the principle mediators of bone cell function since their biosynthesis and release from bone cells and associated tissues can be induced by several cytokines as well as systemic factors. PGE₂, which is synthesized from arachidonic acid, is a potent stimulator of bone resorption and, to date, is the primary PG affecting bone metabolism. The PGs also influence the production and action of insulin-like growth factors (IGFs), which are major bone-derived growth factors (4). Once secreted and deposited in bone matrix, the IGFs are released during osteoclastic bone resorptive activity and could act in an autocrine or paracrine fashion to cause new bone formation and matrix production (18). Thus, IGFs, in concert with other bone growth factors, play an essential role in the coupling of bone formation to bone resorption. The relationship between PGs and IGFs is important in the maintenance of skeletal mass during aging, as well as being vital in optimizing acquisition of bone mass during critical stages of skeletal growth and development.

Cytokines, Growth Factors, and Osteoclastogenesis. Cytokines are extracellular signaling proteins that act on nearby target cells at low concentrations in an autocrine or paracrine fashion in cell-to-cell communications. One of the principle cellular responses produced by the action of cytokines is the synthesis and release of PGE₂.

The cytokines and growth factors involved in bone modeling and remodeling include epidermal growth factor (EGF), fibroblast growth factors (bFGF, FGF-1, and FGF-2), interferon- γ (IFN- γ), interleukins (IL-1, IL-4, IL-6, IL-10, and IL-11), platelet-derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), tumor necrosis factor- α (TNF- α), insulin-like growth factors (IGF-I and IGF-II), osteoclast differentiation factor (ODF, also known as OPGL [osteoprotegerin ligand], RANKL [receptor activator of NF κ B ligand], and TRANCE [TNF-related activation-induced cytokine]), and macrophage colony-stimulating factor (M-CSF). Most of these, such as IL-1 (19), IL-4 (20), IL-6 (21, 22), IL-11 (23, 24), TNF (9, 25, 26), EGF (27), bFGF (28), FGF-2 (29), PDGF (30), and M-CSF (31) stimulate bone resorption. Some, such as IGF-I and IGF-II (7, 30, 32, 33), FGF-2 (34), and TGF- β (35, 36) enhance bone formation, while others (PDGF and TGF- β) also stimulate proliferation and differentiation of collagen-synthesizing cells. Though most of the members of the interleukin family promote bone resorption, IL-10 was reported to inhibit osteoclast formation by abolishing the dif-

ferentiation of precursor cells demonstrated with a coculture system of mouse bone marrow cells and primary osteoblastic cells (37).

The recent discovery of ODF, a membrane bound/soluble protein produced by osteoblastic and stromal cells that stimulates osteoclastogenesis, and osteoprotegerin (OPG, also known as OCIF [osteoclastogenesis inhibitory factor]), a soluble ODF receptor that binds with ODF and blocks its effect on osteoclast formation, impart greater insight in the mechanisms of osteoclast differentiation and function (38). ODF appears to be a common mediator of osteoclast formation induced by many osteotropic hormones and cytokines such as PTH (39, 40), glucocorticoids (16), TNF- α , IL-1 (41), IL-6 (42), and IL-11 (43). OPG, a decoy receptor for ODF, works reciprocally with ODF to regulate the induction of mature osteoclastic cells by various factors.

It is believed that the ratio of ODF/OPG may be a regulatory mechanism controlling bone resorption. For example, PTH upregulates the expression of ODF, but downregulates OPG mRNA expression in mouse bone cells and a mouse stromal cell line ST2, which results in the stimulation of osteoclast formation (40). Hofbauer and colleagues (16) showed that glucocorticoids promote osteoclastogenesis by inhibiting OPG and concurrently stimulating ODF production by osteoblastic lineage cells, resulting in enhanced bone resorption. ODF has also been found to be involved in inflammatory and degenerative bone/joint diseases. ODF expressed on synovial fibroblasts is involved in rheumatoid bone destruction by inducing osteoclastogenesis (44). ODF is expressed by both synovial fibroblasts and by activated T lymphocytes derived from synovial tissues from patients with rheumatoid arthritis (RA), but not from normal synovial tissues. These synovial cells may contribute directly to the expansion of osteoclast precursors and to the formation and activation of osteoclasts at sites of bone erosion in RA (45). Evidence also suggests that the stimulatory effect of PGE₂ on osteoclastogenesis may be mediated by inhibition of OPG expression in bone cells. PGE₂ downregulated OPG mRNA level in human bone marrow stromal cells (hBMSC) (46) and PGE₂ decreased OPG expression in mouse calvarial osteoblasts that supported an increase in osteoclastogenesis (47).

Nagai *et al.* (48) showed that ODF participates in enhanced bone resorption in humoral hypercalcemia of malignancy. When cultured in media conditioned by SCC-4 and T3M-1 Cl.2 cells (carcinoma squamous cell lines), HL60 human promyeloblastic leukemia cells differentiated into osteoclastic-like cells. The anti-ODF antibody inhibited differentiation of HL60 cells, indicating that ODF contributes to the induction of the osteoclastic phenotype observed in these cells.

IGFs. The IGFs are paracrine or autocrine regulatory polypeptides of cells. IGFs are mitogenic and stimulate differentiation in a variety of cell types. Pituitary growth hormone (GH) controls tissue biosynthesis and secretion of IGF-I postnatally and it is through IGF-I that the tissue

effects of GH are mediated. Liver under the influence of GH maintains serum concentrations of IGF-I. Much of the circulating IGF is bound to plasma IGF-binding proteins (IGFBP).

Both IGF-I and IGF-II are conserved in skeletal tissue of vertebrates, including the chicken, human, and rat (13, 32, 49). The amount of IGF-I and IGF-II produced by bone cells is species dependent. In the human, neonatal mouse, and chicken, more IGF-II than IGF-I is produced in the skeletal tissues, but the adult mouse and rat have more IGF-I than IGF-II in skeletal extracts (49). While IGF-II is generally more abundant than IGF-I (50), IGF-I appears to be under greater regulatory control in bone (17, 51). For example, PGE₂ (0.01–1 μ M) elevated IGF-I mRNA and polypeptide levels by 1.9- to 4.7-fold; however, PGE₂ did not increase IGF-II mRNA or polypeptide levels in bone organ cultures of fetal rat calvaria (51).

IGF-I plays an important role in maintaining bone mass. Serum IGF-I and IGFBP-3 were shown to correlate positively with bone mineral density (BMD) of the lumbar spine after age, body mass index, and menopause duration were taken into account for the analysis (52). In healthy postmenopausal women, Garnero (53) reported that decreased serum concentrations of IGF-I were strongly associated with an increased risk of osteoporotic fractures, independent of BMD. It is well recognized that IGF-I level in circulation decreases with age. The reduction of the anabolic process mediated by IGF-I may account for the slow and progressive loss of bone mass that takes place after menopause (54).

A lower IGF-I level was associated with lower bone and lean body mass in hip fracture patients than in an age-matched group (55). Low BMD is one of the most significant of many factors contributing to the incidence of hip fractures. Resistance training in older women with low bone density resulted in increased IGF-I level and greater strength gain (56). The IGF-I level of these women was significantly lower than an age-matched healthy normal group before training.

Eicosanoids: Proper Balance for Optimal Skeletal Health. Certain eicosanoids (prostaglandins and leukotrienes) also exert stimulatory effects on bone formation and resorption. In 1970, Klein and Raisz (57) reported that PGE₁, PGE₂, PGA₁, and PGF_{1 α} increased the release of ⁴⁵Ca into the media from cultured fetal rat bone. Since then, numerous studies have demonstrated that PGE stimulates bone formation as well as bone resorption (6, 58, 59). For example, PGE₂ stimulated collagen synthesis in cultured rat calvariae (60) and osteoblastic cells (61), and also increased the proliferation of osteoblasts in culture (62). PGE₂ was reported to increase cortical bone mass and intracortical bone remodeling in both intact and ovariectomized rats (63), and increased proximal tibial metaphyseal bone area in osteopenic ovariectomized rats (64). PGE₂ at 3 mg/kg body wt per day increased tibial shaft cortical bone formation rate by enhancing modeling activity in aged male rats (65).

On the other hand, PGEs also stimulate bone resorption. Raisz *et al.* (6) reported that infusion of PGE₂ at a high concentration depressed osteogenesis in fetal rat calvariae. Human subjects given PGE₁ treatment (10 µg of lipo-PGE₁ intravenously daily for 14 d or twice a week for 7 weeks) did not demonstrate an increase in bone formation, but showed an increase in bone resorption (66). PGE₂ has been shown to mediate the effects of 1,25-(OH)₂vitamin D₃ (67), cytokines (TNF-α [68] and IL-3 [67]), and growth factors (TGF-β [69], PDGF [70], and bFGF [71]) in enhancing bone resorption. Elevated production of PGE₂ has been associated with several osteolytic disorders in humans, including bone loss associated with dental cysts, failing joint prostheses, chronic osteomyelitis, and certain neoplasms of bone (58). The stimulatory effect of rhBMP-2 on osteoblast (isolated from human periodontal ligament) differentiation was modulated by local PGE₂ levels; that is, at lower levels (10⁻¹⁰ to 10⁻⁸ M) PGE₂ enhanced ALPase activity in cell culture and at a higher concentration (10⁻⁶ M), suppressed osteoblast differentiation (72). Thus, PGE₂ effects on bone formation in animal models seems to be dose related—stimulatory at low concentrations and inhibitory at high concentrations (60, 73, 74).

PGE₂ is an important factor in mediating the effects of several osteolytic cytokines such as IL-1, IL-6, and TNF-α, and calcitropic hormones. PGE₂ stimulates the release of IL-6, an essential factor in osteoclastogenesis, from various mesenchymal cell lines (MC3T3-E1, ST2, UMR-106, and fibroblastic L929) (75). In human osteoblast (MG-63 cells) cell culture, anti-PGE₂ antibody markedly reduced the IL-1β-stimulated production of IL-6 (76). In the same study, IL-1β also induced cyclooxygenase-2 (COX-2) expression, PGE₂ production, and EP₁ receptor signaling prior to IL-6 production. NS-398, a selective COX-2 inhibitor, suppressed the production of PGE₂ and IL-6 in this study.

PGE₂ is an essential factor in osteoclastogenesis. Osteoclast formation stimulated by 1,25-(OH)₂vitamin D₃ or PTH was reduced 60% to 70% in marrow cultures of mice lacking the COX-2 gene relative to cultures from wild-type mice with the intact COX-2 gene (77). Inhibition of osteoclast formation was reversed by the addition of exogenous PGE₂.

PGE₂ also appears to have a role in estrogen-deficient bone loss. PGE₂ accelerated bone resorption in estrogen deficiency. In ovariectomized (OVX) mice, ODF expression in bone marrow stromal cells (78) and pre-B cells (79) was enhanced by elevated production of PGE₂ in bone marrow induced by increased concentrations of pro-inflammatory cytokines such as IL-1 and TNF-α (80, 81). In another study, Kawaguchi *et al.* (82) showed that ovariectomy potentiated PGE₂ production in mouse calvarial osteoblastic cell cultures. This evidence indicates that estrogen deficiency not only enhanced the local production of pro-inflammatory cytokines, but also increased the susceptibility of bone tissue to their catabolic actions.

PGE₂ effects on bone cell formation and maturation are

mediated through different PGE₂ receptors. Four subtypes of PGE₂ receptors have been identified in bone: EP₁, EP₂, EP₃ (EP_{3α}, EP_{3β}, and EP_{3γ}), and EP₄. These receptors transmit the effect of PGE₂ through different signaling pathways: EP₁ activates the 1,3,5-inositol phosphate (IP₃) second messenger through calcium mobilization, EP₂ and EP₄ through the activation of adenylate cyclase, and EP₃ by inhibition (α- and β-subtype) or inhibition/activation of adenylate cyclase subtype γ (83–87).

The differentiation and proliferation of osteoblast and osteoclast cells is achieved in part by interactions between PGE₂ and its receptors in osteoblastic and marrow stromal cells. For example, PGE₂ stimulated osteoblast differentiation (bone nodule formation), but inhibited its proliferation through the EP₁-IP₃ pathway in cells from young rats while it inhibited differentiation, but stimulated proliferation through the EP₂/EP₄-cAMP pathway in cells regardless of the age of the donor animal (88). Miyaura *et al.* (89) showed that PGE₂ stimulated bone resorption by a cAMP-dependent mechanism via the EP₄ receptor, and a marked reduction in PGE₂ induced bone resorption was found in the calvarial and long bone cultures from EP₄ gene knockout mice. In another study, Sakuma (90) showed that PGE₂ enhanced osteoclast formation through its EP₄ subtype on osteoblasts. Osteoblast-mediated bone resorption induced by PGE₂ also appears to involve EP₂. PGE₂ showed a modest effect on the expression of ODF mRNA in osteoblastic and bone marrow stromal cell cultures obtained from EP₂ knockout mice (91). Suzawa *et al.* (92) also showed that PGE-stimulated bone resorption is partially mediated by EP₂ through the induction of ODF via a cAMP signaling pathway in mouse calvarial cultures. The current understanding of PGE₂ indicates effects on osteoclastogenesis that are mediated by its EP₄ receptor; however, the EP₂ subtype may have a role in this process.

Though EP₄ has a major role in osteoclastogenesis, there are still pathways that mediate the formation of osteoclasts independent of this receptor. Sakuma and coworkers (90) reported that both 1,25-(OH)₂vitamin D₃ and PTH induced osteoclast formation in bone marrow cell cultures in an EP₄ knockout mouse model.

Similar to the PGs, leukotrienes (LTs), the metabolites of the 5-lipoxygenase (5-LO) pathway, also participate in the local control of bone metabolism (93–95). In most cases, these compounds are believed to be local regulators of bone metabolism by stimulating bone resorption and inhibiting bone formation. Gallwitz *et al.* (94) reported that LTC₄, LTD₄, and 5-HETE stimulated isolated avian osteoclasts to resorb bone. Meghji *et al.* (95) found that LTB₄, LTC₄, LTD₄, 5-HETE, and 12-HETE stimulated bone resorption in calvariae of mice at picomolar concentrations, whereas PGE₂ produced this stimulatory effect at 10 nM. When LTB₄ was injected over the calvaria of mice, there was a significant increase in bone resorption, osteoclast numbers, and eroded surfaces (96). Treatment with BWA4C, a specific inhibitor of 5-LO, resulted in a dramatic decrease in the

number of TRAP-positive mononucleated preosteoclasts compared with the control and sham-treated groups along the antagonist mandibular buccal cortex 4 days after extraction of the rat upper molars unilaterally (97). On the other hand, LTs also affect osteoblast formation so as to have an impact on bone formation. Ren and Dziak (93) demonstrated that LTB_4 inhibited cell proliferation in cultured osteoblasts isolated from rat calvaria in a dose-dependent manner, but it may also interact with PG to regulate osteoblast activity. In addition, the bone-forming capacity of osteoblasts was impaired when fetal rat calvarial cells were cultured in the presence of 5-LO metabolites (98). Since dietary fatty acids can modulate lipoxygenase synthesis, the elevated LTB_4 production associated with inflammatory conditions may be attenuated with long-chain n-3 fatty acids to reduce the bone loss that occurs in these disorders.

Dietary Lipids Alter Local Factors Controlling Bone and Cartilage Metabolism

Lipids play an important role in skeletal biology and bone health. Acidic phospholipids facilitate cartilage mineralization in growth plate (99), and PGs mediate messages from biomechanical forces (59) and aid in regulating anabolic factors, including IGFs (4), to support bone formation and resorption. Emerging evidence from human and animal research support the hypothesis that dietary lipids influence bone modeling and remodeling. Human studies indicate that the dietary intake of certain fatty acids could help to maintain bone mineral density in the elderly (100), and saturated fat intake was associated with greater bone density in children (101). Recent investigations with chicks and rats revealed that polyunsaturated fatty acids (PUFA) and conjugated linoleic acids (CLA) affect histomorphometric measurements of bone modeling (73, 74, 102).

Dietary fat may influence bone metabolism by altering PG biosynthesis (73, 74, 102). The PGs, locally produced from 20-carbon essential fatty acid precursors (20:4n-6 and 20:5n-3) in osteogenic cells, regulate both bone formation and bone resorption (59). In support of the relationships between dietary PUFA, PGs, and bone metabolism, Watkins *et al.* (73, 102) reported that dietary lipids modulated *ex vivo* bone PGE_2 production and the concentration of IGF-I in bone tissues, and led to altered bone formation rates in growing chicks and rats (102). In these experiments, animals given long-chain n-3 fatty acids tended to show an increased rate of bone formation, suggesting a stimulatory effect on osteoblastic activity. The favorable effect of n-3 fatty acids on bone modeling in growing animals is supported by the observation of reduced bone mineral loss in ovariectomized rats supplemented with eicosapentaenoic acid (EPA 20:5n-3) (103). The bone-sparing effect of 20:5n-3 may be associated with diminished bone resorption or increased bone formation.

The PGE_2 produced by osteoblasts stimulates IGF-I synthesis and affects its action to support an anabolic response in bone (51). Studies with dairy fats revealed that

butter fat blended with corn oil reduced *ex vivo* bone PGE_2 production, elevated bone IGF-I concentration, and increased bone formation rates in chicks nearly 60% compared with those given diets higher in n-6 fatty acids (74). The responses observed in bone tissue suggest that moderating the action of n-6 fatty acids (linoleic acid) with long-chain n-3 fatty acids or CLA can benefit bone modeling.

The establishment of the significant role of PGs, especially PGE_2 , in bone biology and physiology and the link between PGE_2 and dietary n-6 and n-3 fatty acids inspired our investigations on the potential interactions between dietary lipids and bone metabolism. Furthermore, it is believed that IGF-I is regulated by PGE_2 to modulate bone formation and bone resorption (4, 59). Recent studies in our laboratory with animals (chicks and rats) and cell cultures (primary avian chondrocytes and MC3T3-E1 osteoblastic-like cells) revealed that n-6 and n-3 PUFA modified fatty acid composition of tissues and cells, affected the capacity of bone to produce PGE_2 at the tissue level, and altered histomorphometric measurements of bone formation parameters (73, 74, 102, 104).

Several studies showed that dietary lipids transform the fatty acid composition of bone compartments, which would impact the local production of factors influencing bone modeling in experimental animals. Watkins *et al.* (73) reported that an increased production of bone PGE_2 in tibia of chicks given a semi-purified diet containing soybean oil high in n-6 PUFA was associated with a lower rate of bone formation compared with that of chicks given a low dietary ratio of n-6/n-3 fatty acids. Furthermore, dietary n-3 PUFA was reported to lower the concentration of arachidonic acid (AA) in bone (73) and cartilage (105), and depress *ex vivo* PGE_2 production in bone organ culture. Chicks fed a blend of menhaden oil plus safflower oil in a semi-purified diet had a lower concentration of AA, but higher concentrations of 20:5n-3 and 22:6n-3 in cortical bone polar lipids compared with those given soybean oil.

Li *et al.* (102) recently reported that dietary n-6 and n-3 PUFA treatments influenced not only PGE_2 , but also IGF-I concentration and bone histomorphometric measurements in growing rats. *Ex vivo* PGE_2 production was higher in rats given a diet high in n-6 PUFA (n-6/n-3 = 7.3) and serum IGF-I concentration was suppressed compared with those in the high n-3 PUFA treatment (n-6/n-3 = 1.8). In addition, rats fed diets high in n-6 PUFA had a lower ash weight per millimeter bone length in humeri compared with those fed n-3 PUFA. These findings suggest that excessive consumption of n-6 PUFA could have a negative effect on bone metabolism by increasing bone resorptive activity through elevated endogenous production of PGE_2 . The observations in rats are consistent with the results in the chicken.

In another rat feeding study, *ex vivo* PGE_2 production in bone organ culture was significantly reduced in rats given diets with a lower dietary ratio of n-6/n-3 fatty acids (n-6/n-3 = 1.2–2.6) compared with those on diets with a higher dietary ratio (n-6/n-3 = 10–24) (104). Regression analysis

revealed a significant positive correlation between *ex vivo* production of PGE₂ and the ratio of AA/EPA in bone, but a significant negative correlation between bone formation rate and either the ratio of AA/EPA or PGE₂ in bone. Moreover, the activity of serum bone-specific alkaline phosphatase was greater in rats given a diet high in n-3 fatty acids, which further supports the positive action of these fatty acid on bone formation. These results demonstrated that the dietary ratio of n-6/n-3 fatty acids modulates bone PGE₂ production and the activity of serum bone-specific alkaline phosphatase in growing rats.

Enrichment of avian epiphyseal chondrocytes with linoleic acid (LA), AA, and EPA affected collagen synthesis in a dose-dependent fashion (73, 106). The LA and AA treatments reduced collagen synthesis, but EPA appeared to stimulate synthesis. Production of PGE₂ was reduced by EPA treatment, while LA and AA increased PGE₂ relative to the “no fatty acid” enrichment. In our laboratory, experiments on the MC3T3-E1 osteoblast-like cell line revealed that PGE₂ biosynthesis was decreased in 20-day, post-confluent cultures upon treatment with EPA when compared with treatment with AA plus IL-1 α (107). The EPA-treated cells tended to have increased levels of alkaline phosphatase activity and osteocalcin level when compared with cells supplemented with AA plus IL-1 α . Hence, enrichment of osteoblast-like cells with n-6 PUFA resulted in greater capacity to synthesize PGE₂, which appears to decrease cell activity.

Investigations with PUFA and epiphyseal (growth) cartilage and chondrocytes also indicate that dietary lipids affect cartilage metabolism in influencing bone modeling. Experiments on growth cartilage demonstrated that this tissue selectively accumulates dietary fatty acids (105, 108). These results suggest that chondrocytes are either sensitive to excess n-6 fatty acids or to an overproduction of PGE₂ (106). Growth cartilage in children and young animals contains small amounts of n-6 fatty acids, but a relatively high concentration of 20:3n-9 (Mead acid) (109). The concentration of Mead acid is not reduced in growth cartilage of growing animals given diets adequate or enriched in linoleic acid (18:2n-6) (105). Furthermore, supplementation of growth cartilage chondrocytes with linoleic or arachidonic acids depressed collagen synthesis (106), but these cells showed greater collagen synthesis when enriched with long-chain n-3 fatty acids or CLA (110, 111).

Reported findings on modulation of PGE₂ biosynthesis in bone tend to corroborate our results with PUFA treatments. Several studies have shown an increase in osteoblastic bone formation markers when PGE₂ production is decreased or inhibited (62, 112–115). Alam *et al.* (116) reported in rat alveolar bone that dietary PUFA alters fatty acid composition and PGE₂ production. Moreover, rats given diets supplemented with the n-3 fatty acid DHA demonstrated increased bone marrow cellularity (117). The n-3 fatty acids significantly slowed orthodontic tooth movement, which is effected by PGE₂-induced bone resorption in

rats compared with those given diets high in n-6 fatty acids (118). Fish oil significantly lowered serum IL-6, TNF- α , and PGE₂ compared with corn oil in the MRL/lpr autoimmune prone mice (a model for rheumatoid arthritis) (119). Vitamin E further potentiated the suppressive effect of n-3 fatty acids in this study. EPA also suppressed the expression of TNF mRNA in LPS-stimulated RAW 64.7 cells (a mouse macrophage cell line), presumably by suppressing PGE₂ production (120). These data support a positive role of n-3 fatty acids on the modulation of PGE₂ action in maintaining optimal bone health.

Dietary PUFA and Human Bone Health

Osteoporosis. Osteoporosis occurs in both women and men. Postmenopausal women have the greatest risk of developing this disease. Osteoporosis is a condition of decreased bone mass that is prevalent in postmenopausal women and places them at risk for fractures, representing a significant public health problem. Extensive research has been conducted to find a cure for the disease, however, optimizing bone development in the young and reducing bone resorption to maintain bone mass and restore skeletal integrity in the older are still the best means to control the disease. Although more effective treatments are becoming available today for osteoporosis, such as different formulations of hormone replacement therapy (HRT), bisphosphonates, and novel formulations of calcitonin, reducing the existing risk factors is still a preferred approach (121). The best deterrent for osteoporosis is for women to build strong bones early in life by consuming a well-balanced diet (vitamin D, calcium, n-6 and n-3 fatty acids, and phytochemicals) and to follow a routine exercise program pre- and postmenopause. Thus far, direct evidence of any beneficial effect of dietary n-3 fatty acids on human osteoporosis is still lacking. However, experiments using animal and cell culture models, and epidemiological data suggest promising applications of n-3 PUFA on this widespread public health problem.

The primary pathogenesis involved in postmenopausal osteoporosis is an uncoupling of bone formation and resorption, which means that the bone resorption rate exceeds that for bone formation. The effect of n-3 fatty acids on bone formation and/or bone resorption was examined in both normal and ovariectomized rats. Iwami-Morimoto *et al.* (122) studied alveolar bone resorption in 4-week-old rats given diets supplemented with 10% of either fish oil or corn oil for 6 weeks. Dietary fish oil reduced osteoclastic activity (OC number was only 60% of control) and subsequent alveolar bone resorption (80% of control). In ovariectomized female Sprague-Dawley rats, normal or low calcium diets with or without added EPA (approximately 160 mg/day/kg) were administered for 35 days (103). Bone weight of femur and tibia decreased significantly in the low calcium group, but the decrease was inhibited in the EPA group given low calcium. Bones from rats given EPA with a low calcium diet were as strong as those from rats on a normal diet in the

bone rupture test and were stronger than those from rats given a low calcium diet (103). These results suggest that an EPA-enriched diet prevented the loss of bone weight and strength caused by estrogen deficiency as would occur during postmenopause in women. In another study (123), sham-operated or ovariectomized 11-week-old female Sprague-Dawley rats were given diets supplemented with fatty acids (linoleic acid as control, a diester of γ -linolenic acid or EPA) with or without subcutaneous estrogen implant. The rats on the diester diets (containing diesters of γ -linolenic acid or EPA) and diester plus estrogen implant showed increased calcium/femur and reduced urinary deoxypyridinoline and hydroxyproline excretion compared with the sham-operated. Consequently, n-3 fatty acids worked synergistically with estrogen to exert a stimulatory effect on bone mineral deposition and an inhibitory effect on bone resorption.

These studies suggest that using n-3 fatty acid supplements, which are antagonistic to AA in the sense of eicosanoid action, could help maintain bone mineral content after menopause in women. Considering the results from these ovariectomized rat studies (inhibitory to bone resorption) and our findings on n-3 fatty acids in bone modeling (promoting bone formation), it is plausible that consuming diets rich in n-3 fatty acids will help to build and maintain a healthy skeleton in the human.

Inflammatory and Degenerative Bone/Joint Disease. Although osteoporosis is a major disease for postmenopausal women, rheumatoid arthritis (RA) and osteoarthritis (OA) affect millions of people worldwide. Rheumatoid arthritis afflicts peripheral joints in a symmetric distribution and osteoarthritis occurs mainly in weight-bearing joints. The bone and cartilage loss taking place in these disease processes is induced by eicosanoids, lymphokines, and free radicals, which also modulate immune response, influence cell proliferation, and stimulate collagenase and protease secretion (124).

Inflammatory cytokines (e.g. IL-1, a major player in OA and RA) are known to inhibit chondrocyte proliferation (125) and induce cartilage degradation, for which part of the response may be mediated by PGE₂ (126). Excess production of PGE₂ is linked to joint pathology (rheumatoid arthritis), known to exacerbate inflammatory responses, and results in a net loss of proteoglycan from articular cartilage (126). Elevated production of PGE₂ also has been shown to be associated with several osteolytic disorders in human, including bone loss associated with dental cysts (127), failing joint prostheses (128), and certain neoplasms (58, 129). The fact that selective COX-2 inhibitors gave satisfactory relief of symptoms in both osteoarthritis and rheumatoid patients (130, 131) suggests that eicosanoids participate in the inflammatory process of these severe bone/joint diseases. COX-2 and its product PGE₂ appear to be a common link between the two disease states and since it is possible to regulate the activity and expression of COX-2, this en-

zyme is a potential target for dietary intervention in optimizing bone formation and controlling bone disease.

Dietary intervention with n-3 fatty acids demonstrates consistent positive effects on inflammatory joint diseases. n-3 PUFA acts as a competitive inhibitor of eicosanoid biosynthesis in the treatment of RA. Several studies evaluating n-3 PUFA dietary supplements ranging from 3 to 6 g/day showed a modest, but rather consistent beneficial effect of these fatty acids in joint disease (132–141). At the same time, the syntheses of pro-inflammatory factors IL-1, IL-2, and TNF in cartilage tissue were suppressed by dietary supplementation with fish oil containing both EPA and DHA (142). Dietary fish oil supplementation given to rheumatoid arthritis patients resulted in a 19% to 20% reduction of neutrophil LTB₄ production from baseline and a decrease of 38.5% to 40.6% of macrophage IL-1 production (143). The use of flaxseed in domestic food preparation for 4 weeks also reduced the production of TNF- α and IL-1 β by 30% in healthy volunteers (144). In addition, recent clinical trials indicate that some patients with RA are able to discontinue nonsteroidal anti-inflammatory drug NSAID use while receiving a source of n-3 fatty acids (145), suggesting that the mode of n-3 fatty acid action in RA patients could be related to eicosanoid biosynthesis. One explanation for this phenomenon is that the EPA metabolite PGE₃ is much less inflammatory compared with PGE₂ (146). Lowering PGE₂ in the diseased joint with diets rich in long-chain n-3 fatty acids could further benefit RA patients by reducing bone resorption since PGE₂ stimulates osteoclast activity, which results in secondary osteoporosis (145). Since PGE₂ activation of the IGF-I/IGFBP axis may play an important role in cartilage biology and collagen and proteoglycan synthesis (147), dietary fatty acids may also be important for supporting joint repair. Investigations are needed to describe the effects of nutraceutical fatty acids and the ratio of n-6/n-3 fatty acids on cartilage biology, joint disease, and ligament healing since dietary sources of these fatty acids exert potent effects on prostanoid biosynthesis in controlling cell activity in these processes.

New information on prostanoid formation and NSAID action resides in understanding the regulation and expression of cyclooxygenase. Two isoforms of this enzyme exist (COX-1 and COX-2). The COX-1 is a constitutive enzyme responsible for generating PGs that act physiologically, while COX-2, an inducible enzyme, is stimulated by cytokines, growth factors, and tumor promoters. The COX-2 isoform is responsible for production of PGE₂ that is associated with inflammatory reactions (148) and cancer (149, 150).

Anti-inflammatory supplements, including nutraceutical n-3 fatty acids, are associated with decreased pathogenesis of rheumatoid arthritis (with subsequent secondary osteoporosis), reduced inflammatory diseases (141, 145, 151), and lowered cancer risk (152). Incorporation of n-3 fatty acids into articular cartilage chondrocytes membranes resulted in a dose-dependent reduction in the expression and

activity of proteoglycan degrading enzymes, the expression of inflammatory cytokines TNF- α and IL-1, and the expression of COX-2, but not COX-1 (153). A common link between these diseases resides in the regulation/expression of COX-2. For example, multiple lines of evidence indicate that upregulation of COX-2 contributes to tumorigenesis and inflammation (148, 154), providing tissue levels of prostanoid precursors that influence formation of the pro-inflammatory PGE₂. In addition, chronic aspirin (a COX inhibitor) users have reduced incidence of colorectal cancer (150). Both COX-1 and COX-2 inhibitors suppress experimental mouse skin carcinogenesis, and permanent over activation of arachidonic acid metabolism appears to be the driving force for tumor development (155). Moreover, metastasis of cancer to bone is a frequent outcome of breast (about two-thirds of patients with metastatic breast cancer have bone involvement) and prostate malignancies (156, 157). The metastasis is often associated with significant morbidity (severe bone pain and pathologic fractures) due to osteolysis, and the metastatic target bone is continually being remodeled under the influence of local and systemic factors (158).

Interactions Between PUFA and Other Dietary Factors: Phytoestrogen Isoflavonoids

Dietary factors such as calcium and vitamin D have long been linked to the prevention of osteoporosis, a disease associated with decreased bone content and increased bone fracture risk. However, despite the essential role of these two factors, populations with the highest calcium consumption also have higher osteoporosis-related incidence of limb fractures in the world (159, 160). It is logical to hypothesize, therefore, that other dietary factors present in foods have beneficial effects on bone health in those populations with relatively low rates of osteoporosis. Epidemiological studies indicate that populations consuming a diet high in long-chain n-3 fatty acids and soy products, a rich source of genistein, have a lower risk for cardiovascular disease and cancer, as well as osteoporosis (160–163).

Dietary phytoestrogens are plant-derived compounds that exert physiological effects similar to native estrogen. Genistein, a phytoestrogen rich in soy products, has been shown to be as active as estrogen in maintaining bone mass in ovariectomized rats (164). Moreover, genistein suppresses osteoclastic activity *in vitro* and *in vivo* (165), and the anabolic effect of genistein on bone compartments was inhibited by tamoxifen, an anti-estrogen agent, which further confirmed that the effect of genistein may be mediated through an estrogen-like action (166). Furthermore, isoflavones (e.g., genistein) possess antioxidant properties (167, 168) and they may contribute to better bone health by reducing the formation of free radicals and lipid peroxides that depress osteoblastic activity (110, 111). Therefore, one could speculate that phytoestrogens may serve as an anti-resorptive agent to decrease bone resorption, which would

help maintain bone mass postmenopause. Although the research on soy and bone health is promising, investigators have yet to establish a clear hypothesis for its action and more recent studies suggest a beneficial effect on bone formation.

Genistein has a potent inhibitory effect on PTH-, PGE₂- and vitamin D-induced osteoclast-like cell formation in mouse marrow cultures (169). Genistein, acting also as a protein tyrosine kinase inhibitor, selectively reduced COX-2 expression without modification of COX-1 after induction by PMA (phorbol ester activator of PKC) and IL-1 (bone resorption inducer) in human endothelial cells (170). Other evidence also indicates that genistein could inhibit the expression of COX-2 in various cell systems. For example, genistein prevented IL-1 induced expression of COX-2 and production of PGE₂ in human islets (171), and inhibited PGE₂ synthesis in NRK cells (a fibroblastic clone) when induced by EGF (172). Genistein also inhibited COX-2 synthesis and activity in rats with endotoxic shock (173), completely blocked the production of PGE₂ in macrophages stimulated by LPS (174), and reduced COX activity in endothelial cells from newborn pig (175). These findings support the hypothesis that genistein has a general negative effect on PGE₂ production, which may downregulate osteoclastic activity or moderate prostanoid production to favor bone formation.

Summary

Significant changes have occurred over the past few decades in the fat composition of the food supply, in agricultural methods of food production, and in the eating habits of industrialized societies. These changes upset the dietary balance of n-6 to n-3 fatty acids consumed prior to the industrialization era. Based on food disappearance data (per capita food disappearance data from the USDA), the dietary ratio of n-6/n-3 fatty acids has decreased from 12.4:1 in 1985 to 10.6:1 in the U.S. in 1994 (176). However, the present dietary ratio of n-6/n-3 fatty acids may be far from the optimal recommended dietary intake of n-3 fatty acids to protect against chronic disease risk (177).

This review presented information that n-3 fatty acids improved bone metabolism in animals and reduced the symptoms of certain bone/joint diseases in the human. The positive effects of long-chain n-3 PUFA appear to be, in part, associated with downregulating PGE₂ formation in *ex vivo* rat bone organ culture and in osteoblast-like cell cultures. The modulation of prostanoid synthesis from arachidonic acid is linked to increased bone formation in growing rats and osteoblast cell activity in culture. The prospect of new n-3 fatty acid research that evaluates effects on biochemical and molecular factors involved in osteoblast differentiation, bone modeling/remodeling, and disease processes may reveal novel roles for these nutraceutical fatty acids in skeletal health.

1. U.S. Department of Health and Human Services National Center for Health Statistics. DHHS Publication no. (PHS) 96-1232. 1995.
2. Simopoulos AP. Evolutionary aspects of omega-3 fatty acids in the food supply. *Prostaglandins Leukot Essent Fatty Acids* **60**:421-429, 1999.
3. Baron R. Anatomy and ultrastructure of bone. In: Favus MJ, Ed. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism* (2nd edition). New York: Raven Press, pp3-9, 1993.
4. Baylink DJ, Finkelman RD, Mohan S. Growth factors to stimulate bone formation. *J Bone Miner Res* **8**:S565-S572, 1993.
5. Mundy GR. Cytokines and growth factors in the regulation of bone remodeling. *J Bone Miner Res* **8**:S505-S510, 1993.
6. Raisz LG. Bone cell biology: New approaches and unanswered questions. *J Bone Miner Res* **8**:S457-S465, 1993.
7. Canalis E. Regulation of bone remodeling. In: Favus MJ Ed. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism* (2nd edition). New York: Raven Press, pp33-37, 1993.
8. Blair HC, Schlesinger PH, Ross FP, Teitelbaum SL. Recent advances toward understanding osteoclast physiology. *Clin Orthop* **294**:7-22, 1993.
9. Watrous DA, Andrews BS. The metabolism and immunology of bone. *Semin Arthritis Rheum* **19**:45-65, 1989.
10. Nilsson A, Ohlsson C, Isaksson OG, Lindahl A, Isgaard J. Hormonal regulation of longitudinal bone growth. *Eur J Clin Nutr* **48**:S150-S158, 1994.
11. Chow J, Tobias JH, Colston KW, Chambers TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. *J Clin Invest* **89**:74-78, 1992.
12. Raisz LG. Recent advances in bone cell biology: Interactions of vitamin D with other local and systemic factors. *Bone Miner* **9**:191-197, 1990.
13. Kream BE, Petersen DN, Raisz LG. Parathyroid hormone blocks the stimulatory effect of insulin-like growth factor-I on collagen synthesis in cultured 21-day fetal rat calvariae. *Bone* **11**:411-415, 1990.
14. Klaushofer K, Hoffmann O, Gleispach H, Leis HJ, Czerwenka E, Koller K, Peterlik M. Bone-resorbing activity of thyroid hormones is related to prostaglandin production in cultured neonatal mouse calvaria. *J Bone Miner Res* **4**:305-312, 1989.
15. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. *Ann Intern Med* **112**:352-364, 1990.
16. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology* **140**:4382-4389, 1999.
17. Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, Kolakowski LF, Jr., Lodish HF, Goldring SR. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. *Science* **254**:1022-1024, 1991.
18. Linkhart TA, Mohan S, Baylink DJ. Growth factors for bone growth and repair: IGF, TGF beta and BMP. *Bone* **19**:1S-12S, 1996.
19. Marusic A, Raisz LG. Cortisol modulates the actions of interleukin-1 alpha on bone formation, resorption, and prostaglandin production in cultured mouse parietal bones. *Endocrinology* **129**:2699-2706, 1991.
20. Kaji Y, Ikeda K, Ikeda T, Kawakami K, Sasaki K, Shindo M, Hatake K, Harada M, Motoyoshi K, Mori S, Norimatsu H, Takahara J. IL-4, but not vitamin D₃, induces monoblastic cell line UG3 to differentiate into multinucleated giant cells on osteoclast lineage. *J Cell Physiol* **182**:214-221, 2000.
21. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T. IL-6 is produced by osteoblasts and induces bone resorption. *J Immunol* **145**:3297-3303, 1990.
22. Grey A, Mitnick MA, Masiukiewicz U, Sun BH, Rudikoff S, Jilka RL, Manolagas SC, Insogna K. A role for interleukin-6 in parathyroid hormone-induced bone resorption in *in vivo*. *Endocrinology* **140**:4683-4690, 1999.
23. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. *J Cell Physiol* **175**:247-254, 1998.
24. Hill PA, Tumber A, Papaioannou S, Meikle MC. The cellular actions of interleukin-11 on bone resorption *in vitro*. *Endocrinology* **139**:1564-1572, 1998.
25. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: Structure-function relationship(s). *Microsc Res Technol* **50**:184-195, 2000.
26. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. *J Biol Chem* **275**:4858-4864, 2000.
27. Lorenzo JA, Quinton J, Sousa S, Raisz LG. Effects of DNA and prostaglandin synthesis inhibitors on the stimulation of bone resorption by epidermal growth factor in fetal rat long-bone cultures. *J Clin Invest* **77**:1897-1902, 1986.
28. Simmons HA, Raisz LG. Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones. *J Bone Miner Res* **6**:1301-1305, 1991.
29. Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. *Rheumatology* **38**:714-720, 1999.
30. Canalis E, McCarthy TL, Centrella M. Effects of platelet-derived growth factor on bone formation *in vitro*. *J Cell Physiol* **140**:530-537, 1989.
31. Besse A, Trimoreau F, Faucher JL, Praloran V, Denizot Y. Prostaglandin E₂ regulates macrophage colony stimulating factor secretion by human bone marrow stromal cells. *Biochim Biophys Acta* **1450**:444-451, 1999.
32. McCarthy TL, Centrella M, Canalis E. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. *Endocrinology* **124**:301-309, 1989.
33. Canalis E, Centrella M, McCarthy TL. Regulation of insulin-like growth factor-II production in bone cultures. *Endocrinology* **129**:2457-2462, 1991.
34. Dunstan CR, Boyce R, Boyce BF, Garrett IR, Izbiccka E, Burgess WH, Mundy GR. Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. *J Bone Miner Res* **14**:953-959, 1999.
35. Centrella M, McCarthy TL, Canalis E. Transforming growth factor beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. *J Biol Chem* **262**:2869-2874, 1987.
36. Fuller K, Lean JM, Bayley KE, Chambers TJ. A role for TGF beta 1 in osteoclast differentiation and survival. *J Cell Sci* **113**:2445-2453, 2000.
37. Hong MH, Williams H, Jin CH, Pike JW. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. *J Bone Miner Res* **15**:911-918, 2000.
38. Dunstan CR. Osteoprotegerin and osteoprotegerin ligand mediate the local regulation of bone resorption. *Endocrinologist* **10**:18-26, 2000.
39. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. *Endocrinology* **140**:3552-3561, 1999.
40. Kanzawa M, Sugimoto T, Kanatani M, Chihara K. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. *Eur J Endocrinol* **142**:661-664, 2000.
41. Koide M, Murase Y, Yamato K, Noguchi T, Okahashi N, Nishihara T. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. *Biochem Biophys Res Commun* **259**:97-102, 1999.
42. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N. Modulation of osteoclast differentiation by local factors. *Bone* **17**:87S-91S, 1995.
43. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. *Endocrinology* **139**:4743-4746, 1998.
44. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. *Arthritis Rheum* **43**:259-269, 2000.
45. Gravalles EM, Manning C, Tsay A, Naito A, Pan C, Amento E,

- Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. *Arthritis Rheum* **43**:250–258, 2000.
46. Brandstrom H, Jonsson KB, Ohlsson C, Vidal O, Ljunghall S, Ljunggren O. Regulation of osteoprotegerin mRNA levels by prostaglandin E₂ in human bone marrow stroma cells. *Biochem Biophys Res Commun* **247**:338–341, 1998.
 47. Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, Akatsu T. Transforming growth factor- β 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. *Biochem Biophys Res Commun* **252**:747–752, 1998.
 48. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. *Biochem Biophys Res Commun* **269**:532–536, 2000.
 49. Bautista CM, Baylink DJ, Mohan S. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: A potential candidate for fixing IGF-II in human bone. *Biochem Biophys Res Commun* **176**:756–763, 1991.
 50. Mohan S, Baylink DJ. Bone growth factors. *Clin Orthop* **263**:30–48, 1991.
 51. McCarthy TL, Centrella M, Raisz LG, Canalis E. Prostaglandin E₂ stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone. *Endocrinology* **128**:2895–2900, 1991.
 52. Kim JG, Shin CS, Choi YM, Moon SY, Kim SY, Lee JY. The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60. *Clin Endocrinol* **51**:301–307, 1999.
 53. Garnero P, Sornay-Rendu E, Delmas PD. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. *Lancet* **355**:898–899, 2000.
 54. Calo L, Castrignano R, Davis PA, Carraro G, Pagnin E, Giannini S, Semplicini A, D'Angelo A. Role of insulin-like growth factor-I in primary osteoporosis: A correlative study. *J Endocrinol Invest* **23**:223–227, 2000.
 55. Hedstrom M. Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-I levels. *Acta Physiol Scand* **167**:347–350, 1999.
 56. Parkhouse WS, Coupland DC, Li CM, Vanderhoek KJ. IGF-1 bioavailability is increased by resistance training in older women with low bone mineral density. *Mech Aging Dev* **113**:75–83, 2000.
 57. Klein DC, Raisz LG. Prostaglandins: Stimulation of bone resorption in tissue culture. *Endocrinology* **86**:1436–1440, 1970.
 58. Norrdin RW, Jee WS, High WB. The role of prostaglandins in bone *in vivo*. *Prostaglandins Leukot Essent Fatty Acids* **41**:139–149, 1990.
 59. Marks SC, Jr., Miller SC. Prostaglandins and the skeleton: The legacy and challenges of two decades of research. *Endocr J* **1**:337–344, 1993.
 60. Raisz LG, Fall PM. Biphasic effects of prostaglandin E₂ on bone formation in cultured fetal rat calvariae: Interaction with cortisol. *Endocrinology* **126**:1654–1659, 1990.
 61. Hakeda Y, Nakatani Y, Kurihara N, Ikeda E, Maeda N, Kumegawa M. Prostaglandin E₂ stimulates collagen and non-collagen protein synthesis and prolyl hydroxylase activity in osteoblastic clone MC3T3-E1 cells. *Biochem Biophys Res Commun* **126**:340–345, 1985.
 62. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H. Role of endogenous PGE₂ in osteoblastic functions of a clonal osteoblast-like cell, MC3T3-E1. *Prostaglandins Leukot Essent Fatty Acids* **50**:169–172, 1994.
 63. Jee WS, Mori S, Li XJ, Chan S. Prostaglandin E₂ enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. *Bone* **11**:253–266, 1990.
 64. Mori S, Jee WS, Li XJ, Chan S, Kimmel DB. Effects of prostaglandin E₂ on production of new cancellous bone in the axial skeleton of ovariectomized rats. *Bone* **11**:103–113, 1990.
 65. Yao W, Jee WSS, Zhou H, Lu J, Cui L, Setterberg R, Liang T, Ma Y. Anabolic effect of prostaglandin E₂ on cortical bone of aged male rats comes mainly from modeling-dependent bone gain. *Bone* **25**:697–702, 1999.
 66. Takahashi M, Hoshino H, Ishihara C, Kushida K, Inoue T. The effect of prostaglandin E₁ on human bone metabolism: Evaluation by biochemical markers for bone turnover. *Endocr Res* **26**:119–128, 2000.
 67. Collins DA, Chambers TJ. Prostaglandin E₂ promotes osteoclast formation in murine hematopoietic cultures through an action on hematopoietic cells. *J Bone Miner Res* **7**:555–561, 1992.
 68. Tashjian AH, Jr., Voelkel EF, Lazzaro M, Goad D, Bosma T, Levine L. Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. *Endocrinology* **120**:2029–2036, 1987.
 69. Tashjian AH Jr., Voelkel EF, Lazzaro M, Singer FR, Roberts AB, Derynck R, Winkler ME, Levine L. Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. *Proc Natl Acad Sci USA* **82**:4535–4538, 1985.
 70. Tashjian AH Jr., Hohmann EL, Antoniadis HN, Levine L. Platelet-derived growth factor stimulates bone resorption via a prostaglandin-mediated mechanism. *Endocrinology* **111**:118–124, 1982.
 71. Hurley MM, Lee SK, Raisz LG, Bernecker P, Lorenzo J. Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. *Bone* **22**:309–316, 1998.
 72. Takiguchi T, Kobayashi M, Nagashima C, Yamaguchi A, Nishihara T, Hasegawa K. Effect of prostaglandin E₂ on recombinant human bone morphogenetic protein-2-stimulated osteoblastic differentiation in human periodontal ligament cells. *J Periodontol Res* **34**:431–436, 1999.
 73. Watkins BA, Shen CL, Allen KG, Seifert MF. Dietary (n-3) and (n-6) polyunsaturates and acetylsalicylic acid alter *ex vivo* PGE₂ biosynthesis, tissue IGF-I levels, and bone morphometry in chicks. *J Bone Miner Res* **11**:1321–1332, 1996.
 74. Watkins BA, Shen CL, McMurtry JP, Xu H, Bain SD, Allen KG, Seifert MF. Dietary lipids modulate bone prostaglandin E₂ production, insulin-like growth factor-I concentration and formation rate in chicks. *J Nutr* **127**:1084–1091, 1997.
 75. Gruber R, Nothegger G, Ho GM, Willheim M, Peterlik M. Differential stimulation by PGE₂ and calcemic hormones of IL-6 in stromal/osteoblastic cells. *Biochem Biophys Res Commun* **270**:1080–1085, 2000.
 76. Takaoka Y, Niwa S, Nagai H. Interleukin-1 beta induces interleukin-6 production through the production of prostaglandin E₂ in human osteoblasts, MG-63 cells. *J Biochem* **126**:553–558, 1999.
 77. Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, Pilbeam CC. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. *J Clin Invest* **105**:823–832, 2000.
 78. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinoshita M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* **95**:3597–3602, 1998.
 79. Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y. Prostaglandin E₂ induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ligand on pre-B cells: Implications for accelerated osteoclastogenesis in estrogen deficiency. *J Bone Miner Res* **15**:1321–1329, 2000.
 80. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis. *N Engl J Med* **332**:305–311, 1995.
 81. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. *J Biol Chem* **271**:28890–28897, 1996.
 82. Kawaguchi H, Pilbeam CC, Vargas SJ, Morse EE, Lorenzo JA, Raisz LG. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. *J Clin Invest* **96**:539–548, 1995.
 83. Watabe A, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, Ito S, Narumiya S, Ichikawa A. Cloning and expression of cDNA for a mouse EP₁ subtype of prostaglandin E receptor. *J Biol Chem* **268**:20175–20178, 1993.
 84. Katsuyama M, Nishigaki N, Sugimoto Y, Morimoto K, Negishi M, Narumiya S, Ichikawa A. The mouse prostaglandin E receptor EP₂

- subtype: Cloning, expression, and northern blot analysis. *FEBS Lett* **372**:151–156, 1995.
85. Sugimoto Y, Namba T, Honda A, Hayashi Y, Negishi M, Ichikawa A, Narumiya S. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP₃ subtype. *J Biol Chem* **267**:6463–6466, 1992.
 86. Ichikawa A, Sugimoto Y, Negishi M. Molecular aspects of the structures and functions of the prostaglandin E receptors. *J Lipid Mediat Cell Signal* **14**:83–87, 1996.
 87. Irie A, Sugimoto Y, Namba T, Harazono A, Honda A, Watabe A, Negishi M, Narumiya S, Ichikawa A. Third isoform of the prostaglandin-E-receptor EP₃ subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. *Eur J Biochem* **217**:313–318, 1993.
 88. Fujieda M, Kiriu M, Mizuochi S, Hagiya K, Kaneki H, Ide H. Formation of mineralized bone nodules by rat calvarial osteoblasts decreases with donor age due to a reduction in signaling through EP₁ subtype of prostaglandin E₂ receptor. *J Cell Biochem* **75**:215–225, 1999.
 89. Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T. Impaired bone resorption to prostaglandin E₂ in prostaglandin E receptor EP₄-knockout mice. *J Biol Chem* **275**:19819–19823, 2000.
 90. Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, Ushikubi F, Narumiya S, Segi E, Sugimoto Y, Ichikawa A, Nakao K. Crucial involvement of the EP₄ subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. *J Bone Miner Res* **15**:218–227, 2000.
 91. Li XD, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CRJ, Breyer RM, Raisz LG. Knockout of the murine prostaglandin EP₂ receptor impairs osteoclastogenesis *in vitro*. *Endocrinology* **141**:2054–2061, 2000.
 92. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T. The role of prostaglandin E receptor subtypes (EP₁, EP₂, EP₃, and EP₄) in bone resorption: An analysis using specific agonists for the respective EPs. *Endocrinology* **141**:1554–1559, 2000.
 93. Ren W, Dziak R. Effects of leukotrienes on osteoblastic cell proliferation. *Calcif Tissue Int* **49**:197–201, 1991.
 94. Gallwitz WE, Mundy GR, Lee CH, Qiao M, Roodman GD, Raftery M, Gaskell SJ, Bonewald LF. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. *J Biol Chem* **268**:10087–10094, 1993.
 95. Meghji S, Sandy JR, Scutt AM, Harvey W, Harris M. Stimulation of bone resorption by lipoxygenase metabolites of arachidonic acid. *Prostaglandins* **36**:139–149, 1988.
 96. Garcia C, Boyce BF, Gilles J, Dallas M, Qiao M, Mundy GR, Bonewald LF. Leukotriene B₄ stimulates osteoclastic bone resorption both *in vitro* and *in vivo*. *J Bone Miner Res* **11**:1619–1627, 1996.
 97. Franchi-Miller C, Saffar JL. The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling. *Bone* **17**:185–191, 1995.
 98. Traianedes K, Dallas MR, Garrett IR, Mundy GR, Bonewald LF. 5-Lipoxygenase metabolites inhibit bone formation *in vitro*. *Endocrinology* **139**:3178–3184, 1998.
 99. Wuthier RE. Involvement of cellular metabolism of calcium and phosphate in calcification of avian growth plate cartilage. *J Nutr* **123**:301–309, 1993.
 100. Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH. Calcium, gammalinolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. *Aging* **10**:385–394, 1998.
 101. Gunnes M, Lehmann EH. Dietary calcium, saturated fat, fiber and vitamin C as predictors of forearm cortical and trabecular bone mineral density in healthy children and adolescents. *Acta Paediatr* **84**:388–392, 1995.
 102. Li Y, Seifert MF, Ney DM, Grahn M, Grant AL, Allen KG, Watkins BA. Dietary conjugated linoleic acids alter serum IGF-I and IGF binding protein concentrations and reduce bone formation in rats fed (n = 6) or (n-3) fatty acids. *J Bone Miner Res* **14**:1153–1162, 1999.
 103. Sakaguchi K, Morita I, Murota S. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. *Prostaglandins Leukot Essent Fatty Acids* **50**:81–84, 1994.
 104. Watkins BA, Li Y, Allen KGD, Hoffmann WE, Seifert MF. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. *J Nutr* **130**:2274–2284, 2000.
 105. Xu H, Watkins BA, Adkisson HD. Dietary lipids modify the fatty acid composition of cartilage, isolated chondrocytes and matrix vesicles. *Lipids* **29**:619–625, 1994.
 106. Watkins BA, Xu H, Turek JJ. Linoleate impairs collagen synthesis in primary cultures of avian chondrocytes. *Proc Soc Exp Biol Med* **212**:153–159, 1996.
 107. Watkins BA, Lippman HE, Le Bouteiller L, Li Y, Seifert MF. Bioactive fatty acids: Role in bone biology and bone cell function. *Prog Lipid Res* **40**:125–148, 2001.
 108. Xu H, Watkins BA, Seifert MF. Vitamin E stimulates trabecular bone formation and alters epiphyseal cartilage morphometry. *Calcif Tissue Int* **57**:293–300, 1995.
 109. Adkisson HD, Risener FS, Jr., Zarrinkar PP, Walla MD, Christie WW, Wuthier RE. Unique fatty acid composition of normal cartilage: Discovery of high levels of n-9 eicosatrienoic acid and low levels of n-6 polyunsaturated fatty acids. *FASEB J* **5**:344–353, 1991.
 110. Seifert MF, Watkins BA. Role of dietary lipid and antioxidants in bone metabolism. *Nutr Res* **17**:1209–1228, 1997.
 111. Watkins BA, Seifert MF, Allen KG. Importance of dietary fat in modulating PGE₂ responses and influence of vitamin E on bone morphometry. *World Rev Nutr Diet* **82**:250–259, 1997.
 112. Evans DB, Thavarajah M, Kanis JA. Involvement of prostaglandin E₂ in the inhibition of osteocalcin synthesis by human osteoblast-like cells in response to cytokines and systemic hormones. *Biochem Biophys Res Commun* **167**:194–202, 1990.
 113. Evans DB, Bunning RA, Russell RG. The effects of recombinant human interleukin-1 beta on cellular proliferation and the production of prostaglandin E₂, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. *Biochem Biophys Res Commun* **166**:208–216, 1990.
 114. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H. Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E₂ synthesis in the clonal osteoblast-like cell line MC3T3-E1. *Prostaglandins Leukot Essent Fatty Acids* **56**:121–125, 1997.
 115. Kajii T, Suzuki K, Yoshikawa M, Imai T, Matsumoto A, Nakamura S. Long-term effects of prostaglandin E₂ on the mineralization of a clonal osteoblastic cell line (MC3T3-E1). *Arch Oral Biol* **44**:233–241, 1999.
 116. Alam SQ, Kokkinos PP, Alam BS. Fatty acid composition and arachidonic acid concentrations in alveolar bone of rats fed diets with different lipids. *Calcif Tissue Int* **53**:330–332, 1993.
 117. Atkinson TG, Barker HJ, Meckling-Gill KA. Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats. *Lipids* **32**:293–302, 1997.
 118. Kokkinos PP, Shaye R, Alam BS, Alam SQ. Dietary lipids, prostaglandin E₂ levels, and tooth movement in alveolar bone of rats. *Calcif Tissue Int* **53**:333–337, 1993.
 119. Venkatraman JT, Chu WC. Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. *J Am Coll Nutr* **18**:602–613, 1999.
 120. Lo CJ, Chiu KC, Fu MJ, Lo R, Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. *J Surg Res* **82**:216–221, 1999.
 121. Hallworth RB. Prevention and treatment of postmenopausal osteoporosis. *Pharm World Sci* **20**:198–205, 1998.
 122. Iwami-Morimoto Y, Yamaguchi K, Tanne K. Influence of dietary n-3 polyunsaturated fatty acid on experimental tooth movement in rats. *Angle Orthod* **69**:365–371, 1999.
 123. Schlemmer CK, Coetzer H, Claassen N, Kruger MC. Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat. *Prostaglandins Leukot Essent Fatty Acids* **61**:381–390, 1999.
 124. Das UN. Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: Relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases. *Prostaglandins Leukot Essent Fatty Acids* **44**:201–210, 1991.
 125. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. *Arthritis Rheum* **33**:305–315, 1990.

126. Fukuda K, Dan H, Saitoh M, Takayama M, Tanaka S. Superoxide dismutase inhibits interleukin-1-induced degradation of human cartilage. *Agents Actions* **42**:71–73, 1994.
127. Formigli L, Orlandini SZ, Tonelli P, Giannelli M, Martini M, Brandi ML, Bergamini M, Orlandini GE. Osteolytic processes in human radicular cysts: Morphological and biochemical results. *J Oral Pathol Med* **24**:216–220, 1995.
128. Shanbhag AS, Macaulay W, Stefanovic-Racic M, Rubash HE. Nitric oxide release by macrophages in response to particulate wear debris. *J Biomed Mater Res* **41**:497–503, 1998.
129. Francini G, Petrioli R, Maioli E, Gonnelli S, Marsili S, Aquino A, Bruni S. Hypercalcemia in breast cancer. *Clin Exp Metastasis* **11**:359–367, 1993.
130. Boutsens Y, Esselinckx W. Novel nonsteroidal anti-inflammatory drugs. *Acta Gastroenterol Belg* **62**:421–424, 1999.
131. Fung HB, Kirschenbaum HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. *Clin Ther* **21**:1131–1157, 1999.
132. Belch JJ, Ansell D, Madhok R, O'Dowd A, Sturrock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A double blind placebo controlled study. *Ann Rheum Dis* **47**:96–104, 1988.
133. Cathcart ES, Gonnerman WA. Fish oil fatty acids and experimental arthritis. *Rheum Dis Clin North Am* **17**:235–242, 1991.
134. Kremer JM. Clinical studies of omega-3 fatty acid supplementation in patients who have rheumatoid arthritis. *Rheum Dis Clin North Am* **17**:391–402, 1991.
135. Magaro M, Altomonte L, Zoli A, Mirone L, De Sole P, Di Mario G, Lippa S, Oradei A. Influence of diet with different lipid composition on neutrophil chemiluminescence and disease activity in patients with rheumatoid arthritis. *Ann Rheum Dis* **47**:793–796, 1988.
136. Cleland LG, French JK, Betts WH, Murphy GA, Elliott MJ. Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. *J Rheumatol* **15**:1471–1475, 1988.
137. van der Tempel H, Tulleken JE, Limburg PC, Muskiet FA, van Rijswijk MH. Effects of fish oil supplementation in rheumatoid arthritis. *Ann Rheum Dis* **49**:76–80, 1990.
138. Skoldstam L, Borjesson O, Kjallman A, Seiving B, Akesson B. Effect of six months of fish oil supplementation in stable rheumatoid arthritis: A double-blind, controlled study. *Scand J Rheumatol* **21**:178–185, 1992.
139. Nielsen GL, Faarvang KL, Thomsen BS, Teglbaerg KL, Jensen LT, Hansen TM, Lervang HH, Schmidt EB, Dyerberg J, Ernst E. The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A randomized, double blind trial. *Eur J Clin Invest* **22**:687–691, 1992.
140. Sperling RI, Weinblatt M, Robin JL, Ravalese J III, Hoover RL, House F, Coblyn JS, Fraser PA, Spur BW, Robinson DR. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. *Arthritis Rheum* **30**:988–997, 1987.
141. Shapiro JA, Koepsell TD, Voigt LF, Dugowson CE, Kestin M, Nelson JL. Diet and rheumatoid arthritis in women: A possible protective effect of fish consumption. *Epidemiology* **7**:256–263, 1996.
142. Andres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van d Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med* **320**:265–271, 1989.
143. Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE, Sherman M. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: Clinical and immunologic effects. *Arthritis Rheum* **33**:810–820, 1990.
144. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. *Am J Clin Nutr* **63**:116–122, 1996.
145. Kremer JM. Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. *Lipids* **31**:S243–S247, 1996.
146. Alexander JW. Immunonutrition: The role of omega-3 fatty acids. *Nutrition* **14**:627–633, 1998.
147. Di Battista JA, Dore S, Morin N, He Y, Pelletier JP, Martel PJ. Prostaglandin E₂ stimulates insulin-like growth factor binding protein-4 expression and synthesis in cultured human articular chondrocytes: Possible mediation by Ca⁺⁺-calmodulin regulated processes. *J Cell Biochem* **65**:408–419, 1997.
148. Hishinuma T, Nakamura H, Sawai T, Uzuki M, Itabash Y, Mizugaki M. Microdetermination of prostaglandin E₂ in joint fluid in rheumatoid arthritis patients using gas chromatography/selected ion monitoring. *Prostaglandins Other Lipid Mediat* **58**:179–186, 1999.
149. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase: A novel approach to cancer prevention. *Proc Soc Exp Biol Med* **216**:201–210, 1997.
150. Krishnan K, Ruffin MT, Brenner DE. Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent. *J Cell Biochem* **28–29**:148–158, 1997.
151. Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis: A 12-month, double-blind, controlled study. *Arthritis Rheum* **37**:824–829, 1994.
152. Rose DP. Dietary fatty acids and prevention of hormone-responsive cancer. *Proc Soc Exp Biol Med* **216**:224–233, 1997.
153. Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Catterson B. n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. *J Biol Chem* **275**:721–724, 2000.
154. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. *Carcinogenesis* **21**:139–146, 2000.
155. Marks F, Furstemberger G, Muller-Decker K. Arachidonic acid metabolism as a reporter of skin irritancy and target of cancer chemoprevention. *Toxicol Lett* **96–97**:111–118, 1998.
156. Altman GB, Lee CA. Strontium-89 for treatment of painful bone metastasis from prostate cancer. *Oncol Nurs Forum* **23**:523–527, 1996.
157. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. *Endocr Relat Cancer* **6**:333–347, 1999.
158. Orr FW, Kostenuik P, Sanchez-Sweetman OH, Singh G. Mechanisms involved in the metastasis of cancer to bone. *Breast Cancer Res Treat* **25**:151–163, 1993.
159. Melton LJ II. Epidemiology of fractures. In: Riggs BL, Melton LJ III, Eds. *Osteoporosis: Etiology, Diagnosis, and Management*. New York: Raven Press, pp133–154, 1988.
160. Fujita T. Osteoporosis in Japan: Factors contributing to the low incidence of hip fracture. *Adv Nutr Res* **9**:89–99, 1994.
161. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. *Ann Med* **29**:95–120, 1997.
162. Anderson JJ, Anthony MS, Cline JM, Washburn SA, Garner SC. Health potential of soy isoflavones for menopausal women. *Public Health Nutr* **2**:489–504, 1999.
163. Bulliyya G, Reddy PC, Reddy KN, Reddanna P. Fatty acid profile and the atherogenic risk in fish consuming and non-fish consuming people. *Indian J Med Sci* **48**:256–260, 1994.
164. Brandi ML. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. *Calcif Tissue Int* **61**:S5–S8, 1997.
165. Blair HC, Jordan SE, Peterson TG, Barnes S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. *J Cell Biochem* **61**:629–637, 1996.
166. Yamaguchi M, Gao YH. Anabolic effect of genistein on bone metabolism in the femoral-metaphyseal tissues of elderly rats is inhibited by the anti-estrogen tamoxifen. *Res Exp Med* **197**:101–107, 1997.
167. Toda S, Shirataki Y. Inhibitory effects of isoflavones on lipid peroxidation by reactive oxygen species. *Phytother Res* **13**:163–165, 1999.
168. Arora A, Valcic S, Cornejo S, Nair MG, Timmermann BN, Liebler DC. Reactions of genistein with alkylperoxyl radicals. *Chem Res Toxicol* **13**:638–645, 2000.
169. Gao YH, Yamaguchi M. Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. *Biochem Pharmacol* **58**:767–772, 1999.
170. Blanco A, Habib A, Levy-Toledano S, Maclouf J. Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. *Biochem J* **312**:419–423, 1995.
171. Corbett JA, Kwon G, Marino MH, Rodi CP, Sullivan PM, Turk J,

- McDaniel ML. Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. *Am J Physiol* **270**:C1581–C1587, 1996.
172. Astruc ME, Lahoua Z. Potentiation by cholesterol and vitamin D₃ oxygenated derivatives of arachidonic acid release and prostaglandin E₂ synthesis induced by the epidermal growth factor in NRK 49F cells: The role of protein kinase C. *Cell Signal* **6**:763–775, 1994.
173. Ruetten H, Thiernemann C. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: A possible role for protein tyrosine kinase. *Br J Pharmacol* **122**:59–70, 1997.
174. Sakamoto W, Fujie K, Nishihira J, Handa H, Ueda N, Yamamoto S. Effect of vitamin E on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated rat macrophages. *Biochim Biophys Acta* **1304**:139–144, 1996.
175. Parfenova H, Balabanova L, Leffler CW. Post-translational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. *Am J Physiol* **274**:C72–C81, 1998.
176. Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, Hargrove RL, Zhao G, Etherton TD. Polyunsaturated fatty acids in the food chain in the United States. *Am J Clin Nutr* **71**:179S–188S, 2000.
177. Simopoulos AP, Leaf A, Salem N Jr. Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. *Ann Nutr Metab* **43**:127–130, 1999.